Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-27T22:28:42.420Z Has data issue: false hasContentIssue false
  • English
  • Français

RETHINKING EPISTEMIC INCENTIVES: HOW PATIENT-CENTERED, OPEN SOURCE DRUG DISCOVERY GENERATES MORE VALUABLE KNOWLEDGE SOONER

Published online by Cambridge University Press:  13 November 2013

Alexandra Bradner
Get access Rights & Permissions [Opens in a new window]

Abstract

Drug discovery traditionally has occurred behind closed doors in for-profit corporations hoping to develop best-selling medicines that recoup initial research investment, sustain marketing infrastructures, and pass on healthy returns to shareholders. Only corporate Pharma has the man- and purchasing-power to synthesize the thousands of molecules needed to find a new drug and to conduct the clinical trials that will make the drug legal. Against this view, individual physician-scientists have suggested that the promise of applied genomics work calls for a new form of social organization – the open source sharing of molecular probes – in order to speed the generation and understanding of new therapeutics. Recent successes in open source drug discovery show it is possible to produce valuable, empirically adequate, and sustainable collective beliefs without secrecy, proprietary attitudes, initial cooperation from Pharma, or outsized monetary incentives. After reviewing and differentiating these successes, I diagnose the source of this healthy new epistemic strategy.

Type
Discussion
Information
Episteme , Volume 10 , Issue 4 , December 2013 , pp. 417 - 439
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Anand, P., Brown, J. D., Lin, C. Y. et al. 2013. ‘BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure.’ Cell, 150(3): 569–82.Google Scholar
Ankeny, R. 2013. ‘Establishing Causes in Medical Practice: The Role of Cases.’ Plenary Address. The Society for Philosophy of Science in Practice, Institute for the History and Philosophy of Science and Technology, Victoria College, University of Toronto, Toronto, Canada, June 27, 2013.Google Scholar
Begley, C. G. and Ellis, L. M. 2012. ‘Drug Development: Raise Standards for Preclinical Cancer Research.’ Nature, 483: 531–3. doi: 10.1038/483531a.CrossRefGoogle ScholarPubMed
Bradner, A. 2012. ‘Using Structure to Understand Justice and Care as Different Worlds.’ Topoi, 32: 111–22.Google Scholar
Bradner, J. 2013. ‘Epigenetic Targets for Cancer: Bromodomain Inhibition in Cancer.’ American Association for Cancer Research Annual Meeting 2013, Washington, DC, video, 29:22, April 8, 2013. Accessed April 18, 2013. http://webcast.aacr.org/console/player/20077?mediaType=podiumVideo&.Google Scholar
Code, L. 2010. ‘Testimony, Advocacy and Ignorance: Thinking Ecologically about Social Knowledge.’ In Haddock, A. et al. (eds), Social Epistemology. Oxford: Oxford University Press. Accessed 4/16/2013 (Oxford Scholarship Online edition, 2011). doi: 10.1093/acprof:oso/9780199577477.001.0001.Google Scholar
Cutler, D. 2007. ‘The Demise of the Blockbuster?’ New England Journal of Medicine, 356:1292–3.Google Scholar
Dana-Farber Cancer Institute. 2010. ‘DFCI Outbound Academic MTA v. 2 2010 Modified for compounds.’ Cambridge, MA: Harvard University.Google Scholar
Dawson, M. A. and Kouzarides, T. 2012. ‘Cancer Epigenetics: from Mechanism to Therapy.’ Cell, 150: 12–27.Google Scholar
Delmore, J. E., Issa, G. C., Lemieux, M. E. et al. 2011. ‘BET Bromodomain Inhibition as a Therapeutic Strategy to target c-Myc.’ Cell, 146: 904–17.Google Scholar
DiBona, C., Ockman, S. and Stone, M. (eds). 1999. Open Sources: Voices from the Open Source Revolution. Sebastopol, CA: O'Reilly & Associates.Google Scholar
Federation for American Societies for Experimental Biology (FASEB). 2013. ‘Sequestration Cuts Biomedical & Biological Research Factsheet.’ Accessed May 16, 2013. http://www.faseb.org/Portals/0/PDFs/opa/Sequestration%20factsheet.pdfGoogle Scholar
Filippakopoulos, P., Qi, J., Picaud, S. et al. 2010. ‘Selective inhibition of BET bromodomains.’ Nature 468: 1067–73.Google Scholar
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Perez-Atayde, A. R. and Fletcher, J. A. 2003. ‘BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.’ Cancer Research, 63: 304–7.Google Scholar
Friend, S. and Schadt, E. 2009. ‘Something Wiki this way comes. Interview by Bryn Nelson.’ Nature 458(7234): 13.Google Scholar
Frye, S. V. 2010. ‘The Art of the Chemical Probe.’ Nature Chemical Biology, 6: 159–61. doi: 10.1038/nchembio.296.CrossRefGoogle ScholarPubMed
Gilligan, C. 1982. In a Different Voice. Cambridge, MA: Harvard University Press.Google Scholar
Goodpaster, K. 1991. ‘Business Ethics and Stakeholder Analysis.’ Business Ethics Quarterly 1: 53–73.Google Scholar
Hacking, I. 1993. ‘Working in a New World.’ In Horwich, P. (ed.), World Changes: Thomas Kuhn and the Nature of Science. Cambridge, MA: MIT Press.Google Scholar
Health Impact Fund (HIF). 2013. ‘Frequently Asked Questions on The Health Impact Fund.’ Accessed May 16, 2013. http://healthimpactfund.com/faq/#no18.Google Scholar
Hull, D. 1988. Science as Process: An Evolutionary Account of the Social and Conceptual Development of Science. Chicago, IL: University of Chicago Press.Google Scholar
Innovative Medicines Initiative (IMI). 2010. ‘Mission.’ Accessed May 14, 2013. http://www.imi.europa.eu/content/mission.Google Scholar
James, W. 1979. The Will to Believe and Other Essays in Popular Philosophy. Cambridge, MA: Harvard University Press.Google Scholar
Kantarjian, H., Fojo, T., Mathiesen, M. and Zwelling, L. 2013. ‘Cancer Drugs in the United States: Justum Pretium – The Just Price.’ Journal of Clinical Oncology. Published online May 6, 2013. Accessed July 15, 2013. http://jco.ascopubs.org/content/early/2013/05/06/JCO.2013.49.1845.Google Scholar
Keller, E. F. 1983. A Feeling for the Organism: The Life and Work of Barbara McClintock. New York: Freeman.Google Scholar
Masters, J. R. W. and Palsson, B. Ø (eds). 1999. Human Cell Culture, Vol. 1–3. Dordrecht: Kluwer Academic.Google Scholar
Masters, J. R. 2002. ‘HeLa Cells 50 years on: The Good the Bad and the Ugly.’ Nature Reviews Cancer 2: 315–319.Google Scholar
Matzuk, M. M., McKeown, M. R., Filippakopoulos, P. et al. 2012. ‘Small-molecule Inhibition of BRDT for Male Contraception.’ Cell 150: 673–84.Google Scholar
Maxmen, A. 2012. ‘Cancer Research: Open Ambition.’ Nature 488(7140): 149–50.Google Scholar
Medicines for Malaria Venture. 2013. ‘Open access for malaria box.’ Accessed July 25, 2013. http://www.mmv.org/malariabox.Google Scholar
Mobley, A., Linder, S. K., Braeuer, R., Ellis, L. M. and Zwelling, L. 2013. ‘A Survey on Data Reproducibility in Cancer Research provides Insights into our Limited Ability to translate Findings from the Laboratory to the Clinic.’ PLoS ONE 8(5): e63221.Google Scholar
Open Source Drug Discovery (OSDD). ‘What is OSDD.’ Accessed May 16, 2013. http://www.osdd.net/about-us.Google Scholar
OpenSourceMalaria. 2013. ‘Story so far.’ Last modified July 10, 2013. Accessed July 25, 2013. http://openwetware.org/wiki/OpenSourceMalaria:Story_so_far.Google Scholar
Prayle, A. P., Hurley, M. N. and Smyth, A. R. 2012. ‘Compliance with Mandatory Reporting of Clinical Trial Results on ClinicalTrials.gov: Cross Sectional Study.’ British Medical Journal 344: d7373.Google Scholar
Prinz, F., Schlange, T. and Asadullah, K. 2011. ‘Believe It or Not: How Much can We Rely on Published Data on Potential Drug Targets?’ Nature Reviews Drug Discovery 10: 712.Google Scholar
Rohde, H., Qin, J., Cui, Y. et al. 2011. ‘Open-source Genomic Analysis Of Shiga-toxin-producing E. coli O104:H4.’ New England Journal of Medicine 365(8): 718–24.Google Scholar
Sage Bionetworks. 2013. ‘About Us.’ Accessed April 19, 2013. http://sagebase.org.Google Scholar
Shrum, W., Genuth, J. and Chompalov, I. 2007. Structures of Scientific Collaboration. Boston, MA: MIT Press.Google Scholar
Skloot, R. 2001. ‘An Obsession with Culture.’ Pitt Magazine March 2001. Accessed May 15, 2013. http://www.pittmag.pitt.edu/mar2001/culture.html.Google Scholar
Sourceforge. 2013. ‘Main page: celera assembler.’ Last modified March 19, 2013. Accessed April 18, 2013. http://sourceforge.net/apps/mediawiki/wgs-assembler/index.php?title=Main_Page.Google Scholar
Stallman, R. 1999. ‘The GNU operating system and the free software movement.’ In DiBona, C., Ockman, S. & Stone, M. (eds), Open Sources: Voices from the Open Source Revolution, pp. 53–70. Sebastopol, CA: O'Reilly & Associates.Google Scholar
Stallman, R. 2002. Free Software, Free Society: Selected Essays of Richard M. Stallman. Boston, MA: GNU Press.Google Scholar
Stegenga, J. 2013. ‘Detecting Harm of Medical Interventions.’ In Science, Policy, Values: Exploring the Nexus. Pre-conference workshop at the Society for Philosophy of Science in Practice, Institute for the History and Philosophy of Science and Technology, Victoria College, University of Toronto, Toronto, Canada, June 26, 2013.Google Scholar
Stiglitz, J. E. ‘How Intellectual Property Reinforces Inequality.’ The New York Times July 14, 2013. Accessed July 15, 2013. http://opinionator.blogs.nytimes.com/2013/07/14/how-intellectual-property-reinforces-inequality/?emc=eta1.Google Scholar
Todd, M. 2012. ‘Molecular craigslist.’ Intermolecular blog. April 19, 2012. Accessed July 25, 2013. http://intermolecular.wordpress.com/2012/04/20/molecular-craigslist/Google Scholar
Westphal, S. P. 2013. ‘Unverified Science; Studies that can't be Replicated create a Problem with Trust – and Funds.’ The Boston Globe July 8, 2013. Accessed July 15, 2013. http://www.bostonglobe.com/opinion/2013/07/07/for-research-useful-has-reproducible/MjyEf0q7HDlWvOTmNFfl8L/story.html.Google Scholar
Woelfle, M., Olliaro, P. and Todd, M. 2011. ‘Open Science is a Research Accelerator.’ Nature Chemistry 3: 745–8.Google Scholar